https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-at-the-40th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/aligos-therapeutics-begins-dosing-with-nash-drug-candidate-alg-055009-in-healthy
https://www.nasdaq.com/press-release/aligos-presents-update-of-chronic-hepatitis-b-pipeline-portfolio-at-hep-dart-2021
https://www.nasdaq.com/press-release/vipergen-establishes-research-partnership-with-aligos-therapeutics-focused-on-dna
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-at-the-piper-sandler-33rd-annual-virtual-healthcare
https://www.nasdaq.com/press-release/aligos-therapeutics-appoints-bridget-martell-ma-m.d.-to-its-board-of-directors-2021
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-virtually-at-the-jefferies-london-healthcare
https://www.nasdaq.com/press-release/aligos-therapeutics-presents-data-for-its-chronic-hepatitis-b-chb-and-nonalcoholic
https://www.nasdaq.com/press-release/aligos-therapeutics-reports-recent-business-progress-and-third-quarter-2021-financial
https://www.nasdaq.com/press-release/aligos-therapeutics-to-announce-third-quarter-2021-results-november-4-2021-2021-10-28
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-data-for-its-clinical-portfolio-targeting-chronic
https://www.nasdaq.com/press-release/aligos-therapeutics-begins-dosing-with-antisense-oligonucleotide-drug-candidate-alg
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-at-the-cantor-virtual-global-healthcare-conference
https://www.nasdaq.com/press-release/aligos-therapeutics-reports-recent-business-progress-and-second-quarter-2021
https://www.nasdaq.com/press-release/aligos-therapeutics-to-announce-second-quarter-2021-results-august-5-2021-2021-07-29
https://www.nasdaq.com/press-release/aligos-therapeutics-announces-pricing-of-%2483.6-million-public-offering-of-common
https://www.nasdaq.com/press-release/aligos-therapeutics-announces-proposed-public-offering-of-common-stock-2021-06-28
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-phase-1-safety-and-pharmacokinetic-data-for-stopstm
https://www.nasdaq.com/press-release/aligos-therapeutics-announces-pipeline-update-and-upcoming-presentations-at-the
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-preliminary-antiviral-activity-of-alg-000184-in
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-at-the-jefferies-virtual-healthcare-conference-2021-05
https://www.nasdaq.com/press-release/aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2021-financial
https://www.nasdaq.com/press-release/aligos-therapeutics-to-announce-first-quarter-2021-results-may-10-2021-2021-05-05
https://www.nasdaq.com/press-release/aligos-therapeutics-appoints-james-scopa-j.d.-mba-to-its-board-of-directors-2021-04
https://www.nasdaq.com/press-release/aligos-therapeutics-begins-dosing-with-capsid-assembly-modulator-drug-candidate-alg
https://www.nasdaq.com/press-release/aligos-therapeutics-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aligos-therapeutics-begins-dosing-with-stopstm-molecule-drug-candidate-alg-010133-in
https://www.nasdaq.com/press-release/aligos-therapeutics-presents-nonclinical-data-for-its-covid-19-therapeutic-in
https://www.nasdaq.com/press-release/aligos-therapeutics-presents-data-for-its-chronic-hepatitis-b-drug-candidates-at-the
https://www.nasdaq.com/press-release/aligos-therapeutics-to-present-at-the-39th-annual-j.p.-morgan-healthcare-conference
https://www.nasdaq.com/press-release/aligos-therapeutics-presents-update-on-development-of-sars-cov-2-therapeutic
https://www.nasdaq.com/press-release/aligos-enters-into-an-exclusive-license-and-research-collaboration-agreement-with
https://www.nasdaq.com/press-release/aligos-therapeutics-presents-data-on-chronic-hepatitis-b-nash-and-hepatocellular
https://www.nasdaq.com/press-release/aligos-therapeutics-announces-presentations-at-the-jefferies-virtual-london
https://www.nasdaq.com/press-release/aligos-therapeutics-is-awarded-eu1.8m-vlaio-grant-to-advance-chronic-hepatitis-b
https://www.nasdaq.com/press-release/aligos-therapeutics-doses-first-subject-in-phase-1-proof-of-concept-study-of-small
